AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25626749 — intervention group
Group type: COMPARATOR
Intervention: Mixed flawless and errorful performances (E)
Number of subjects: 39
Study 25626749 — intervention group
Group type: EXPERIMENTAL
Intervention: Flawless and errorful performances with assessment feedback (FA)
Number of subjects: 39
Study 23582626 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 40 mg and Amlodipine 10 mg (B+A)
Number of subjects: 5714
Study 23582626 — intervention group
Group type: COMPARATOR
Intervention: Benazepril 40 mg and Hydrochlorothiazide 25 mg (B+H)
Number of subjects: 5714
Study 21135284 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (40 mg/m²/d in a 5-minute IV infusion, days 1 through 3, every 21 days)
Number of subjects: 76
Study 21135284 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m²/d in a 30-minute IV infusion, days 1 through 5, every 21 days)
Number of subjects: 76
Study 18766378 — intervention group
Group type: EXPERIMENTAL
Intervention: G10 formula (AHE-based product)
Number of subjects: 27
Study 18766378 — intervention group
Group type: COMPARATOR
Intervention: Ethanolic DEET solution (25% DEET)
Number of subjects: 27
Study 18766378 — intervention group
Group type: COMPARATOR
Intervention: Insect Block 28 (28.5% DEET)
Number of subjects: 27
Study 17062213 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-PA conduit
Number of subjects: 17
Study 17062213 — intervention group
Group type: COMPARATOR
Intervention: BT shunt
Number of subjects: 17
Study 12860545 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament injury
Number of subjects: 33
Study 12860545 — intervention group
Group type: COMPARATOR
Intervention: Control (uninjured teammates)
Number of subjects: 33
Study 10969352 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy
Number of subjects: 37303
Study 10969352 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 37303
Study 10969352 — intervention group
Group type: COMPARATOR
Intervention: Not prescribed antiretroviral therapy
Number of subjects: 37303
Study 10969352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 37303
Study 9177388 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 9177388 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 1438618 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPP (0.25 mg/kg, p.o.)
Number of subjects: 49
Study 1438618 — intervention group
Group type: EXPERIMENTAL
Intervention: DMI (75 mg, i.m.)
Number of subjects: 49
Study 1438618 — intervention group
Group type: COMPARATOR
Intervention: Total sample (including all groups)
Number of subjects: 49
Study 1438618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major depression and panic disorder
Number of subjects: 49
Study 3514648 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model for defining high-risk subgroup
Number of subjects: 77
Study 3514648 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection strategy for screening
Number of subjects: 77
Study 31526825 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 184
Study 31526825 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 184
Study 29153963 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography (SWE)
Number of subjects: 35
Study 29153963 — intervention group
Group type: COMPARATOR
Intervention: B-mode Ultrasound (B-US)
Number of subjects: 35
Study 29153963 — intervention group
Group type: COMPARATOR
Intervention: Power Doppler Ultrasound (PD-US)
Number of subjects: 35
Study 26871460 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term meditation practice
Number of subjects: 0
Study 26871460 — intervention group
Group type: COMPARATOR
Intervention: 8-week course of mindfulness-based stress reduction
Number of subjects: 0
Study 26871460 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of meditation practices
Number of subjects: 0
Study 24782083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 160
Study 24782083 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 22516385 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-based antiperspirant
Number of subjects: 198
Study 22516385 — intervention group
Group type: COMPARATOR
Intervention: Standard care (wash only)
Number of subjects: 198
Study 20150294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 78
Study 20150294 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2000 mg/day)
Number of subjects: 78
Study 17873551 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (3 times per week for 3 months, 30 minutes per session)
Number of subjects: 32
Study 17873551 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 32
Study 16251172 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dosage of rh‐EPO up to 5000 U/kg/wk
Number of subjects: 51
Study 16251172 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of rh‐EPO at 1250 U/kg/wk
Number of subjects: 51
Study 11912262 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin I infusion (8 ng/kg per min) with liberal sodium intake (200 mmol sodium/d)
Number of subjects: 27
Study 11912262 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin I infusion (8 ng/kg per min) with low sodium intake (50 mmol sodium/d)
Number of subjects: 27
Study 10444229 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg per day)
Number of subjects: 0
Study 10444229 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (first-generation antihistamine)
Number of subjects: 0
Study 7600138 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg at 0.1 mg/min infusion rate)
Number of subjects: 14
Study 7600138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2195865 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 7100
Study 631690 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotec syrup 2.5 mg
Number of subjects: 2
Study 631690 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotec syrup 5.0 mg
Number of subjects: 2
Study 631690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30394106 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted 1:1 intervention (Desi-Sehat) delivered in English, Hindi, and Urdu
Number of subjects: 93
Study 30394106 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-targeted 1:1 intervention (Desi-Sehat)
Number of subjects: 93
Study 30745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile augmented reality simulator used for local anesthesia training, 2 hours weekly for four weeks.
Number of subjects: 41
Study 30745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile augmented reality simulator
Number of subjects: 41
Study 30745346 — intervention group
Group type: COMPARATOR
Intervention: Conventional educational methods (Control)
Number of subjects: 41
Study 30745346 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 29169472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled xenon (40% end-tidal concentration) combined with hypothermia (33°C) for 24 hours
Number of subjects: 110
Study 29169472 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia treatment alone
Number of subjects: 110
Study 25780939 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership support program
Number of subjects: 318
Study 25780939 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 318
Study 23739030 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP plus 12 months of enhanced continuing care (ECC)
Number of subjects: 152
Study 23739030 — intervention group
Group type: COMPARATOR
Intervention: IOP treatment as usual (TAU)
Number of subjects: 152
Study 20865421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (first-time)
Number of subjects: 90
Study 20218030 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Check intervention (5 to 10 interactions)
Number of subjects: 130
Study 20218030 — intervention group
Group type: COMPARATOR
Intervention: Control activity (2 drug-profile reviews)
Number of subjects: 130
Study 17094752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless procedure using a tailed 6F double-J stent
Number of subjects: 24
Study 17094752 — intervention group
Group type: COMPARATOR
Intervention: Small tube procedure using an 8.2 pigtail nephrostomy tube
Number of subjects: 24
Study 15998166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (letter notification)
Number of subjects: 6518
Study 15998166 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6518
Study 11376174 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 160
Study 11376174 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy, second surgery, or chemotherapy
Number of subjects: 160
Study 9279624 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more doses of BCG vaccine
Number of subjects: 0
Study 9279624 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of BCG vaccine
Number of subjects: 0
Study 9279624 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of BCG vaccine
Number of subjects: 0
Study 9279624 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of BCG vaccine
Number of subjects: 0
Study 7509619 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-based chemotherapy
Number of subjects: 281
Study 7509619 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index
Number of subjects: 281
Study 3534212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Number of subjects: 20
Study 3534212 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl
Number of subjects: 20
Study 2545451 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT-4237 rotavirus vaccine
Number of subjects: 203
Study 2545451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 31892639 — intervention group
Group type: EXPERIMENTAL
Intervention: COPDAE+ (severe acute exacerbation of COPD)
Number of subjects: 3734
Study 31892639 — intervention group
Group type: EXPERIMENTAL
Intervention: COPDAE- (no acute exacerbation of COPD)
Number of subjects: 3734
Study 31892639 — intervention group
Group type: COMPARATOR
Intervention: non-COPD (control group)
Number of subjects: 3734
Study 31892639 — intervention group
Group type: EXPERIMENTAL
Intervention: COPDAE+ (aged <65)
Number of subjects: 3734
Study 30698771 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (3 sessions)
Number of subjects: 33
Study 30698771 — intervention group
Group type: COMPARATOR
Intervention: Prolotherapy with 20% dextrose (1 session)
Number of subjects: 33
Study 29119960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrostatic therapy
Number of subjects: 94
Study 29119960 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 94
Study 25850708 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Loteprednol Etabonate 0.5%
Number of subjects: 75
Study 25850708 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A 0.05%
Number of subjects: 75
Study 23800263 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stress
Number of subjects: 8
Study 23800263 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 22079655 — intervention group
Group type: EXPERIMENTAL
Intervention: ¹²³I‐ADAM SPECT imaging over 1 month
Number of subjects: 28
Study 22079655 — intervention group
Group type: EXPERIMENTAL
Intervention: ¹²³I‐ADAM SPECT imaging over 1 year
Number of subjects: 28
Study 22079655 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test-retest scans
Number of subjects: 28
Study 22079655 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian correlation analysis
Number of subjects: 28
Study 19920107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 mcg/kg, single dose)
Number of subjects: 34
Study 19920107 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 mcg/kg/day, daily until neutrophil recovery)
Number of subjects: 34
Study 16491284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate treatment (annual dose, 9 mg/kg body weight) for 2-4 years
Number of subjects: 50
Study 16491284 — intervention group
Group type: COMPARATOR
Intervention: Untreated OI patients (matched for OI type and age)
Number of subjects: 50
Study 15187818 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat fibre supplementation (10.5 g/day for 1 week, then 21 g/day for 4 weeks)
Number of subjects: 42
Study 15187818 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard high-fibre diet)
Number of subjects: 42
Study 11068116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 130
Study 9248263 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 w/v% black tea extract gargle twice daily (at 8 a.m. and 5 p.m.)
Number of subjects: 259
Study 9248263 — intervention group
Group type: COMPARATOR
Intervention: Normal daily routine (control group)
Number of subjects: 259
Study 8448094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine
Number of subjects: 30
Study 8448094 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 30
Study 2427841 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg once daily)
Number of subjects: 55
Study 2427841 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 to 400 mg once daily)
Number of subjects: 55
Study 31301881 — intervention group
Group type: EXPERIMENTAL
Intervention: UHR group
Number of subjects: 285
Study 30281106 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing-Up Milk (GUMLi)
Number of subjects: 160
Study 30281106 — intervention group
Group type: COMPARATOR
Intervention: Cow Milk (CM)
Number of subjects: 160
Study 28409398 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pacing strategy
Number of subjects: 15
Study 28409398 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pacing strategy
Number of subjects: 15
Study 25680597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiation therapy (EBRT)
Number of subjects: 1240
Study 25680597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 1240
Study 25680597 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant treatment
Number of subjects: 1240
Study 25680597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1240
Study 23553459 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg, twice daily) for 12 weeks
Number of subjects: 107
Study 20384441 — intervention group
Group type: EXPERIMENTAL
Intervention: hp-hMG
Number of subjects: 136
Study 20384441 — intervention group
Group type: COMPARATOR
Intervention: r-FSH
Number of subjects: 136
Study 20384441 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH + hp-hMG
Number of subjects: 136
Study 18445988 — intervention group
Group type: EXPERIMENTAL
Intervention: imidafenacin 0.1 mg twice daily
Number of subjects: 14
Study 17028508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 183
Study 12756930 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Number of subjects: 26
Study 12756930 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Number of subjects: 26
Study 12756930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (4 weeks and 6 weeks of physical therapy)
Number of subjects: 26
Study 12756930 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of physical therapy
Number of subjects: 26
Study 10418715 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 20
Study 7485935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger BP 0.5g
Number of subjects: 108
Study 7485935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger BP 1.0g
Number of subjects: 108
Study 7485935 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 108
Study 1973591 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (ST) 4.2 micrograms/min for 72 hours
Number of subjects: 54
Study 1973591 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (VP) 0.4 IU/min for 72 hours
Number of subjects: 54
Study 6785794 — intervention group
Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 30
Study 6785794 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 30
Study 29857780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Number of subjects: 24
Study 29857780 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Number of subjects: 24
Study 29857780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) inhaled solution
Number of subjects: 24
Study 29857780 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) inhaled solution
Number of subjects: 24
Study 27163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel 400 mg with a low-fat meal
Number of subjects: 36
Study 27163497 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel 400 mg with a high-fat meal
Number of subjects: 36
Study 27163497 — intervention group
Group type: COMPARATOR
Intervention: Orteronel 400 mg under fasting conditions
Number of subjects: 36
Study 25059340 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) prior to TAVI
Number of subjects: 310
Study 25059340 — intervention group
Group type: COMPARATOR
Intervention: No PCI (control arm)
Number of subjects: 310
Study 25059340 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 310
Study 22561565 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic self-management education
Number of subjects: 248
Study 22561565 — intervention group
Group type: COMPARATOR
Intervention: Routine community education (Control)
Number of subjects: 248
Study 20931154 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 62
Study 17653960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg topical testosterone therapy daily (2 cm Andro‐Feme cream)
Number of subjects: 36
Study 17653960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16173911 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus behavioral counseling during primary care visits
Number of subjects: 874
Study 16173911 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus behavioral counseling that included telephone contact and behavioral classes
Number of subjects: 874
Study 16173911 — intervention group
Group type: COMPARATOR
Intervention: Physician advice (control group)
Number of subjects: 874
Study 16173911 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (including control)
Number of subjects: 874
Study 11902621 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward comparisons with worse-off others
Number of subjects: 0
Study 9850940 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 0
Study 9850940 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 0
Study 9850940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg daily
Number of subjects: 31
Study 8084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg daily
Number of subjects: 31
Study 8084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (5 persons) in patients with low K value
Number of subjects: 31
Study 8084808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (7 persons) in patients with low K value
Number of subjects: 31
Study 8084808 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 normal subjects)
Number of subjects: 31
Study 2510264 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.d.
Number of subjects: 91
Study 2510264 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 91
Study 806790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipostabil
Number of subjects: 73
Study 806790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipostabil forte
Number of subjects: 73
Study 806790 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparations
Number of subjects: 73
Study 29699518 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device (OVD)
Number of subjects: 60
Study 29699518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroimplantation
Number of subjects: 60
Study 29699518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27929610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.5 mg/kg over 40 minutes)
Number of subjects: 34
Study 25185507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by practitioners
Number of subjects: 36
Study 25185507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) diagnostic studies
Number of subjects: 36
Study 25185507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by practitioners with >400 studies
Number of subjects: 36
Study 25185507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution esophageal manometry (HRM) assessment by experts involved in the Chicago Classification system
Number of subjects: 36
Study 23525964 — intervention group
Group type: EXPERIMENTAL
Intervention: PTQ™
Number of subjects: 35
Study 23525964 — intervention group
Group type: EXPERIMENTAL
Intervention: Durasphere(®)
Number of subjects: 35